Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

In an Imperfect World: Strategies for Psychiatric Clinical Trials


Studies involving psychiatry drugs may be uniquely challenging.

Tweetables from this article:

Tweet: Not all symptomatic improvement in mental disorders can necessarily be tied to the product under study. http://ctt.ec/lf2Zz+ Not all symptomatic improvement in mental disorders can necessarily be tied to the product under study.

Share this!

September 16, 2016 | by Megan Sims

In a perfect world, clinical drug trials draw conclusive results from objective observations. But we don’t live in that world, and we doubt you do, either.

Studies involving psychiatry drugs may be uniquely challenging. Ensuring that trial data accurately captures a compound’s safety and efficacy potential requires that you account for challenges inherent in working with a mentally ill population. Observing changes in the disease under study is partly a subjective process, and that creates risk of undue influence that the patient and/or investigator may not recognize.

To further complicate things, not all symptomatic improvement in mental disorders can necessarily be tied to the product under study. Some changes may result from unrelated factors whose therapeutic effect erodes the efficacy signal of a potential treatment.

On Tuesday, September 20, join two experts from Premier Research for a revealing look at these challenges. Krista Armstrong, Vice President of Strategic Development, and Susan Kozauer, Senior Medical Director, will present Conclusive Results: Strategies for Collecting Quality Data in Psychiatric Clinical Trials. The hour-long session, beginning at 11 a.m. Eastern time, will explore a range of factors that — if identified and mitigated early in the development process — can maximize the potential for conclusive study results. Look for a particular focus on:

  • Study design considerations
  • Site factors
  • Subject selection and eligibility
  • Data surveillance

The neuroscience experts at Premier Research have performed more than 150 neuroscience studies in just the past five years, their work touching more than 27,000 patients afflicted with all major central nervous system disorders. Register today for what is sure to be an informative presentation.

Keywords: Premier Research, Psychiatry, Clinical Trials



        Share this with your colleagues!

        Top 5 Most Impactful Tweets in Healthcare During the Last Week

        May 12, 2017 - This week, we’ll be rounding up 5 of the most impactful tweets in healthcare, to keep you in the loop. This week, the passage of the American Health Care Act stirred up many key healthcare influencers to speak out, nurses appreciation week is underway and WHO celebrates the anniversary of the eradication of smallpox.

        Which Antioxidant is Right for Your Nutraceutical Product?

        May 3, 2017 - For nutraceuticals manufacturers, it’s important to choose a highly-potent antioxidant which is sustainable to produce and can easily be formulated into a number of product forms.

        What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

        April 17, 2017 - Depending on the design and use of a medical device, manufacturers may be required to develop a biological safety evaluation before a device secures regulatory approval. While the main focus of this testing is to assess the biocompatibility of a medical device and the potential risk to the patient, it is imperative that device manufacturers avoid costly and unnecessary testing.


        6 Tips to Overcome Nervousness When Speaking in a Webinar


        Enabling Patient-Centric Digital Transformation in Pharma and Biotech

        The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations

        Respiratory Endpoints, Scientific Leadership and the Asia-Pacific Region

        Imaging Diagnostics and Theranostics: Meeting Clinical Development Challenges

        Copyright © 2016-2017 Honeycomb Worldwide Inc.